Skip to main content
Erschienen in: Journal of Assisted Reproduction and Genetics 5/2020

24.03.2020 | Review

Navigating the body of literature assessing BRCA1/2 mutations and markers of ovarian function: a systematic review and meta-analysis

verfasst von: Christina N. Cordeiro Mitchell, Bailey McGuinness, Eliana Fine, William G. Kearns, Mindy S. Christianson, James Segars, Lisa M. Pastore

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Twelve percent of women in the USA will develop invasive breast cancer in their lifetime, and that risk increases to 80% if they carry a BRCA1 or BRCA2 mutation. BRCA1/2 mutations are thought to potentially affect ovarian reserve and/or fertility.

Methods

PubMed and PubMed Central were searched for publications on ovarian reserve–related outcomes (i.e., AMH and response to controlled ovarian hyperstimulation (COH) protocols) that were reported in relation to BRCA1 and/or BRCA2 mutations from 1950 through May 2019. A meta-analysis was conducted to create forest plots and summary effect measures using Review Manager 5.3.

Results

This article reviews the 16 qualifying publications. There were several fundamental methodological differences in the study designs and outcome details reported in AMH studies. Summary statistics found no difference in AMH levels between BRCA1/2+ women as compared with controls (Z overall test effects p ≥ 0.45). Regarding responses to COH, there were overall non-significantly fewer total and mature numbers of oocytes retrieved in BRCA1/2+ cases as compared with controls (meta-analysis Z overall test effects p ≥ 0.40).

Conclusions

While the summary measures indicate no significant differences in AMH levels between BRCA1/2+ cases and controls, readers should be aware that there are significant methodological differences in the AMH reports. Additionally, the response to COH protocols does not seem to be significantly lower in BRCA1/2 mutation carriers in the existing literature. Continued research on both of these clinical parameters would be beneficial for patient counseling.
Literatur
2.
Zurück zum Zitat Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet. 1996;14(2):188–90.CrossRefPubMed Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet. 1996;14(2):188–90.CrossRefPubMed
3.
Zurück zum Zitat Whittemore AS, Gong G, John EM, McGuire V, Li FP, Ostrow KL, et al. Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomark Prev. 2004;13(12):2078–83. Whittemore AS, Gong G, John EM, McGuire V, Li FP, Ostrow KL, et al. Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomark Prev. 2004;13(12):2078–83.
4.
Zurück zum Zitat Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694–706.CrossRefPubMed Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694–706.CrossRefPubMed
5.
Zurück zum Zitat Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in White and Black American women ages 35 to 64 years. Cancer Res. 2006;66:8297–308.CrossRefPubMed Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in White and Black American women ages 35 to 64 years. Cancer Res. 2006;66:8297–308.CrossRefPubMed
6.
Zurück zum Zitat de la Noval BD. Potential implications on female fertility and reproductive lifespan in BRCA germline mutation women. Arch Gynecol Obstet. 2016;294(5):1099–103.CrossRefPubMed de la Noval BD. Potential implications on female fertility and reproductive lifespan in BRCA germline mutation women. Arch Gynecol Obstet. 2016;294(5):1099–103.CrossRefPubMed
7.
Zurück zum Zitat Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol. 2010;28(2):240–4.CrossRefPubMed Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol. 2010;28(2):240–4.CrossRefPubMed
8.
Zurück zum Zitat de la Hoya M, Fernandez JM, Tosar A, Godino J, Sanchez de Abajo A, Vidart JA, et al. Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both. Jama. 2003;290(7):929–31.CrossRefPubMed de la Hoya M, Fernandez JM, Tosar A, Godino J, Sanchez de Abajo A, Vidart JA, et al. Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both. Jama. 2003;290(7):929–31.CrossRefPubMed
10.
Zurück zum Zitat Ballal RD, Saha T, Fan S, Haddad BR, Rosen EM. BRCA1 localization to the telomere and its loss from the telomere in response to DNA damage. J Biol Chem. 2009;284(52):36083–98.CrossRefPubMedPubMedCentral Ballal RD, Saha T, Fan S, Haddad BR, Rosen EM. BRCA1 localization to the telomere and its loss from the telomere in response to DNA damage. J Biol Chem. 2009;284(52):36083–98.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat French JD, Dunn J, Smart CE, Manning N, Brown MA. Disruption of BRCA1 function results in telomere lengthening and increased anaphase bridge formation in immortalized cell lines. Genes Chromosom Cancer. 2006;45(3):277–89.CrossRefPubMed French JD, Dunn J, Smart CE, Manning N, Brown MA. Disruption of BRCA1 function results in telomere lengthening and increased anaphase bridge formation in immortalized cell lines. Genes Chromosom Cancer. 2006;45(3):277–89.CrossRefPubMed
12.
Zurück zum Zitat McPherson JP, Hande MP, Poonepalli A, Lemmers B, Zablocki E, Migon E, et al. A role for Brca1 in chromosome end maintenance. Hum Mol Genet. 2006;15(6):831–8.CrossRefPubMed McPherson JP, Hande MP, Poonepalli A, Lemmers B, Zablocki E, Migon E, et al. A role for Brca1 in chromosome end maintenance. Hum Mol Genet. 2006;15(6):831–8.CrossRefPubMed
13.
Zurück zum Zitat Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril. 2013;99(6):1724–8.CrossRefPubMed Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril. 2013;99(6):1724–8.CrossRefPubMed
14.
Zurück zum Zitat Giordano S, Garrett-Mayer E, Mittal N, Smith K, Shulman L, Passaglia C, et al. Association of BRCA1 mutations with impaired ovarian reserve: connection between infertility and breast/ovarian cancer risk. J Adolesc Young Adult Oncol. 2016;5(4):337–43.CrossRefPubMedPubMedCentral Giordano S, Garrett-Mayer E, Mittal N, Smith K, Shulman L, Passaglia C, et al. Association of BRCA1 mutations with impaired ovarian reserve: connection between infertility and breast/ovarian cancer risk. J Adolesc Young Adult Oncol. 2016;5(4):337–43.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Johnson L, Sammel MD, Domchek S, Schanne A, Prewitt M, Gracia C. Antimullerian hormone levels are lower in BRCA2 mutation carriers. Fertil Steril. 2017;107(5):1256–65.e6.CrossRefPubMedPubMedCentral Johnson L, Sammel MD, Domchek S, Schanne A, Prewitt M, Gracia C. Antimullerian hormone levels are lower in BRCA2 mutation carriers. Fertil Steril. 2017;107(5):1256–65.e6.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Lin WT, Beattie M, Chen LM, Oktay K, Crawford SL, Gold EB, et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer. 2013;119(9):1652–9.CrossRefPubMedPubMedCentral Lin WT, Beattie M, Chen LM, Oktay K, Crawford SL, Gold EB, et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer. 2013;119(9):1652–9.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Rzepka-Gorska I, Tarnowski B, Chudecka-Glaz A, Gorski B, Zielinska D, Toloczko-Grabarek A. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res Treat. 2006;100(1):59–63.CrossRefPubMed Rzepka-Gorska I, Tarnowski B, Chudecka-Glaz A, Gorski B, Zielinska D, Toloczko-Grabarek A. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res Treat. 2006;100(1):59–63.CrossRefPubMed
18.
Zurück zum Zitat Hotaling JM, Laufer N, Rosenwaks Z. Introduction: cancer biomarkers and fertility. Fertil Steril. 2018;109(1):4–5.CrossRefPubMed Hotaling JM, Laufer N, Rosenwaks Z. Introduction: cancer biomarkers and fertility. Fertil Steril. 2018;109(1):4–5.CrossRefPubMed
19.
Zurück zum Zitat Podfigurna A, Lukaszuk K, Czyzyk A, Kunicki M, Maciejewska-Jeske M, Jakiel G, et al. Testing ovarian reserve in pre-menopausal women: why, whom and how? Maturitas. 2018;109:112–7.CrossRefPubMed Podfigurna A, Lukaszuk K, Czyzyk A, Kunicki M, Maciejewska-Jeske M, Jakiel G, et al. Testing ovarian reserve in pre-menopausal women: why, whom and how? Maturitas. 2018;109:112–7.CrossRefPubMed
20.
Zurück zum Zitat Victoria M, Labrosse J, Krief F, Cedrin-Durnerin I, Comtet M, Grynberg M. Anti Mullerian hormone: more than a biomarker of female reproductive function. J Gynecol Obstet Hum Reprod. 2019;48(1):19–24.CrossRefPubMed Victoria M, Labrosse J, Krief F, Cedrin-Durnerin I, Comtet M, Grynberg M. Anti Mullerian hormone: more than a biomarker of female reproductive function. J Gynecol Obstet Hum Reprod. 2019;48(1):19–24.CrossRefPubMed
21.
Zurück zum Zitat Derks-Smeets IAP, van Tilborg TC, van Montfoort A, Smits L, Torrance HL, Meijer-Hoogeveen M, et al. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD. J Assist Reprod Genet. 2017. Derks-Smeets IAP, van Tilborg TC, van Montfoort A, Smits L, Torrance HL, Meijer-Hoogeveen M, et al. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD. J Assist Reprod Genet. 2017.
22.
Zurück zum Zitat Wang ET, Pisarska MD, Bresee C, Chen YD, Lester J, Afshar Y, et al. BRCA1 germline mutations may be associated with reduced ovarian reserve. Fertil Steril. 2014;102(6):1723–8.CrossRefPubMedPubMedCentral Wang ET, Pisarska MD, Bresee C, Chen YD, Lester J, Afshar Y, et al. BRCA1 germline mutations may be associated with reduced ovarian reserve. Fertil Steril. 2014;102(6):1723–8.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Lin W, Titus S, Moy F, Ginsburg ES, Oktay K. Ovarian aging in women with BRCA germline mutations. J Clin Endocrinol Metab. 2017;102(10):3839–47.CrossRefPubMedPubMedCentral Lin W, Titus S, Moy F, Ginsburg ES, Oktay K. Ovarian aging in women with BRCA germline mutations. J Clin Endocrinol Metab. 2017;102(10):3839–47.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Phillips K-A, Collins IM, Milne RL, McLachlan SA, Friedlander M, Hickey M, et al. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Hum Reprod. 2016;31(5):1126–32.CrossRefPubMedPubMedCentral Phillips K-A, Collins IM, Milne RL, McLachlan SA, Friedlander M, Hickey M, et al. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Hum Reprod. 2016;31(5):1126–32.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5(172):172ra21.CrossRefPubMedPubMedCentral Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5(172):172ra21.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Choi YS, Park JH, Lee JH, Yoon JK, Yun BH, Park JH, et al. Association between impairment of DNA double strand break repair and decreased ovarian reserve in patients with endometriosis. Front Endocrinol. 2018;9:772.CrossRef Choi YS, Park JH, Lee JH, Yoon JK, Yun BH, Park JH, et al. Association between impairment of DNA double strand break repair and decreased ovarian reserve in patients with endometriosis. Front Endocrinol. 2018;9:772.CrossRef
27.
Zurück zum Zitat Turan V, Bedoschi G, Emirdar V, Moy F, Oktay K. Ovarian stimulation in patients with cancer: impact of letrozole and BRCA mutations on fertility preservation cycle outcomes. Reprod Sci. 2018;25(1):26–32.CrossRefPubMed Turan V, Bedoschi G, Emirdar V, Moy F, Oktay K. Ovarian stimulation in patients with cancer: impact of letrozole and BRCA mutations on fertility preservation cycle outcomes. Reprod Sci. 2018;25(1):26–32.CrossRefPubMed
28.
Zurück zum Zitat Gunnala V, Fields J, Irani M, D’Angelo D, Xu K, Schattman G, et al. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation. Fertil Steril. 2019;111(2):363–71.CrossRefPubMed Gunnala V, Fields J, Irani M, D’Angelo D, Xu K, Schattman G, et al. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation. Fertil Steril. 2019;111(2):363–71.CrossRefPubMed
29.
Zurück zum Zitat Michaelson-Cohen R, Mor P, Srebnik N, Beller U, Levy-Lahad E, Eldar-Geva T. BRCA mutation carriers do not have compromised ovarian reserve. Int J Gynecol Cancer. 2014;24(2):233–7.CrossRefPubMed Michaelson-Cohen R, Mor P, Srebnik N, Beller U, Levy-Lahad E, Eldar-Geva T. BRCA mutation carriers do not have compromised ovarian reserve. Int J Gynecol Cancer. 2014;24(2):233–7.CrossRefPubMed
30.
Zurück zum Zitat van Tilborg TC, Derks-Smeets IA, Bos AM, Oosterwijk JC, van Golde RJ, de Die-Smulders CE, et al. Serum AMH levels in healthy women from BRCA1/2 mutated families: are they reduced? Hum Reprod. 2016;31(11):2651–9.CrossRefPubMed van Tilborg TC, Derks-Smeets IA, Bos AM, Oosterwijk JC, van Golde RJ, de Die-Smulders CE, et al. Serum AMH levels in healthy women from BRCA1/2 mutated families: are they reduced? Hum Reprod. 2016;31(11):2651–9.CrossRefPubMed
31.
Zurück zum Zitat Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA Jr, Desir J, et al. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol. 2018;29(1):237–43.CrossRefPubMed Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA Jr, Desir J, et al. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol. 2018;29(1):237–43.CrossRefPubMed
32.
Zurück zum Zitat Shapira M, Raanani H, Feldman B, Srebnik N, Dereck-Haim S, Manela D, et al. BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles. Fertil Steril. 2015;104(5):1162–7.CrossRefPubMed Shapira M, Raanani H, Feldman B, Srebnik N, Dereck-Haim S, Manela D, et al. BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles. Fertil Steril. 2015;104(5):1162–7.CrossRefPubMed
33.
Zurück zum Zitat Pavone ME, Hirshfeld-Cytron J, Tingen C, Thomas C, Thomas J, Lowe MP, et al. Human ovarian tissue cortex surrounding benign and malignant lesions. Reprod Sci. 2014;21(5):582–9.CrossRefPubMedPubMedCentral Pavone ME, Hirshfeld-Cytron J, Tingen C, Thomas C, Thomas J, Lowe MP, et al. Human ovarian tissue cortex surrounding benign and malignant lesions. Reprod Sci. 2014;21(5):582–9.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat The_Nordic_Cochrane_Centre. Review Manager (RevMan). Version 5.3 ed. Copenhagen: The Cochrane Collaboration; 2014. The_Nordic_Cochrane_Centre. Review Manager (RevMan). Version 5.3 ed. Copenhagen: The Cochrane Collaboration; 2014.
35.
Zurück zum Zitat Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.CrossRefPubMedPubMedCentral Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Cline MS, Liao RG, Parsons MT, Paten B, Alquaddoomi F, Antoniou A, et al. BRCA challenge: BRCA exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet. 2018;14(12):e1007752.CrossRefPubMedPubMedCentral Cline MS, Liao RG, Parsons MT, Paten B, Alquaddoomi F, Antoniou A, et al. BRCA challenge: BRCA exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet. 2018;14(12):e1007752.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Barnes-Kedar I, Bernstein-Molho R, Ginzach N, Hartmajer S, Shapira T, Magal N, et al. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations. Breast Cancer Res Treat. 2018;172(1):151–7.CrossRefPubMed Barnes-Kedar I, Bernstein-Molho R, Ginzach N, Hartmajer S, Shapira T, Magal N, et al. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations. Breast Cancer Res Treat. 2018;172(1):151–7.CrossRefPubMed
Metadaten
Titel
Navigating the body of literature assessing BRCA1/2 mutations and markers of ovarian function: a systematic review and meta-analysis
verfasst von
Christina N. Cordeiro Mitchell
Bailey McGuinness
Eliana Fine
William G. Kearns
Mindy S. Christianson
James Segars
Lisa M. Pastore
Publikationsdatum
24.03.2020
Verlag
Springer US
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 5/2020
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-020-01745-2

Weitere Artikel der Ausgabe 5/2020

Journal of Assisted Reproduction and Genetics 5/2020 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.